Rx License-Rx
← Back to AI Screener Open university listing

LicenseRx asset brief

AAV5 Vector and Uses Thereof

National Institutes of Health Early / Discovery Cell/Gene Therapy
Probability of Success

14% · grade C · Medium data confidence

Model PoS 14% (grade C, medium data confidence). Strongest signals: Indication pull, Licensing readiness. Biggest drag: IP position.

Data maturity (22%) 41

Early / Discovery; human data.

IP position (16%) 30

Protection lapsed or abandoned -- verify freedom to operate.

Modality feasibility (14%) 55

Cell/gene therapy -- high upside, heavy manufacturing and regulatory load.

Indication pull (14%) 70

Infectious Disease -- active buyer appetite.

Competitive whitespace (12%) 74

Multi-modal differentiation.

Translational evidence (12%) 54

Public evidence mentions: human.

Licensing readiness (10%) 94

Listed as available for licensing; established tech-transfer office; 1 public source link(s).

Unlock the full strategic deep dive

Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.

View Operator access See what's included →